Glaukos Co. (NYSE:GKOS) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Glaukos Co. (NYSE:GKOS - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the twelve research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $134.67.

GKOS has been the subject of a number of analyst reports. Mizuho lowered their target price on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a report on Wednesday, April 16th. Morgan Stanley reduced their price target on shares of Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Piper Sandler reduced their price target on shares of Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 15th. Stephens reduced their price target on shares of Glaukos from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. Finally, Stifel Nicolaus reduced their price target on shares of Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st.

Glaukos Trading Down 0.1%

GKOS traded down $0.08 during trading on Friday, reaching $94.88. 1,197,122 shares of the company's stock were exchanged, compared to its average volume of 704,367. The company's fifty day moving average price is $92.86 and its 200-day moving average price is $123.50. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos has a fifty-two week low of $77.10 and a fifty-two week high of $163.71. The firm has a market capitalization of $5.42 billion, a PE ratio of -33.06 and a beta of 0.83.

Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.33) by $0.11. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The firm had revenue of $106.66 million during the quarter, compared to analyst estimates of $102.78 million. During the same quarter in the previous year, the business earned ($0.70) EPS. The business's quarterly revenue was up 24.6% compared to the same quarter last year. As a group, equities analysts forecast that Glaukos will post -1.08 EPS for the current year.

Insider Activity at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of the business's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares of the company's stock, valued at $5,708,568.04. The trade was a 2.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 6.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Glaukos

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Strs Ohio bought a new stake in Glaukos during the 1st quarter worth about $955,000. Intech Investment Management LLC lifted its position in Glaukos by 212.7% during the 1st quarter. Intech Investment Management LLC now owns 92,564 shares of the medical instruments supplier's stock worth $9,110,000 after buying an additional 62,963 shares in the last quarter. Bayforest Capital Ltd bought a new stake in Glaukos during the 1st quarter worth about $141,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Glaukos by 41.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier's stock worth $22,636,000 after buying an additional 67,668 shares in the last quarter. Finally, United Services Automobile Association bought a new stake in shares of Glaukos in the 1st quarter valued at about $342,000. 99.04% of the stock is owned by institutional investors.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.